Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB – Get Free Report) has been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $5.88.
CNTB has been the subject of a number of research reports. Wall Street Zen downgraded Connect Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Oppenheimer lowered their price objective on shares of Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 22nd. HC Wainwright reiterated a “buy” rating on shares of Connect Biopharma in a report on Wednesday, October 28th. Weiss Ratings cut Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Finally, Leerink Partners started coverage on shares of Connect Biopharma in a report on Monday, October 12th. They issued an “outperform” rating and a $4.00 price target on the stock.
Get Our Latest Report on Connect Biopharma
Institutional Trading of Connect Biopharma
Connect Biopharma Stock Performance
Shares of CNTB stock opened at $0.59 on Monday. The company’s fifty day simple moving average is $0.91 and its 200-day simple moving average is $2.06. Connect Biopharma has a 52 week low of $0.55 and a 52 week high of $3.82. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. The company has a market cap of $37.15 million, a PE ratio of -0.52 and a beta of 0.06.
Connect Biopharma (NASDAQ:CNTB – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The company had revenue of $0.74 million for the quarter, compared to analyst estimates of $9.65 million. As a group, equities research analysts anticipate that Connect Biopharma will post -1.05 EPS for the current year.
About Connect Biopharma
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
Further Reading
- Five stocks we like better than Connect Biopharma
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
